Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
A randomized, open-label single-center study investigates the efficacy and safety of
bilateral renal artery sympathetic denervation by catheter-based radiofrequency ablation on
blood pressure and disease progression control in autosomal dominant polycystic kidney
disease(ADPKD). The total number of study subjects will be 100. All of them have diagnosed
with ADPKD and hypertension. Patients will be randomized 1:1 (50 with radiofrequency
ablation(RFA), 50 only with drugs). Change in average office-based measurements of systolic
blood pressure(SBP), average 24-hour systolic blood pressure by ambulatory blood pressure
monitoring (ABPM) , incidence of office systolic blood pressure reductions of ≥10, ≥15 and
≥20 mm Hg , office diastolic blood pressure (DBP), number and dosage of blood pressure
tablets, total kidney volume (TKV), total cyst volume (TCV), pain related to cystic kidneys
and renal function, will be assessed at 12 months of follow-up. The safety variables will be
assessed at every visit of follow-up.